RSV Treatment in Outpatient Settings

Supportive Care Approach

The American Thoracic Society recommends supportive care as the cornerstone of RSV management in outpatient settings, focusing on hydration, fever control, and respiratory support 1, 2

For immunocompromised patients with RSV infection, the Infectious Diseases Society of America considers oral ribavirin as a potential treatment option to reduce progression to lower respiratory tract infection and mortality 1, 3
The Centers for Disease Control and Prevention suggests aerosolized ribavirin (2g every 8 hours or 6g over 18 hours daily for 7-10 days) may be considered in select cases, particularly in hematopoietic stem cell transplant recipients 4
The American Academy of Pediatrics notes that profound lymphopenia (<100 cells/mm³) is associated with progression to lower respiratory tract disease and should prompt closer monitoring 5

The American College of Chest Physicians states that nucleic acid-based testing (PCR) is the reference standard for diagnosis but is not routinely recommended for all outpatients with suspected RSV 1, 2
The Centers for Disease Control and Prevention recommends considering RSV testing in high-risk immunocompromised patients to guide management decisions 4
The American Academy of Family Physicians suggests considering RSV testing in outbreak settings to guide infection control measures 6

The Centers for Disease Control and Prevention recommends implementing strict infection control practices to prevent transmission, including hand hygiene before and after patient contact 6
The Infectious Diseases Society of America advises proper handling and disposal of respiratory secretions 4
The American Academy of Pediatrics recommends advising patients to avoid contact with high-risk individuals (young infants, elderly, immunocompromised) 4

The European Society of Clinical Microbiology and Infectious Diseases warns against unnecessary antibiotic use for viral infections; antibiotics should only be considered if bacterial superinfection is suspected 7
The American Academy of Pediatrics notes that palivizumab has no therapeutic benefit for established RSV infection and should only be used for prophylaxis in specific high-risk groups 8

The American Academy of Pediatrics recommends hospitalization for severe comorbidities or immunocompromised state with moderate-to-severe symptoms 5